GLOMTHERA
LIVE

Serial Number

79445697

Owner

Purespring Therapeutics Limited

Filing Date

Jan 9, 2026

Add to watchlist:

No watchlists yet
View on USPTO

GLOMTHERA Trademark

Serial Number: 79445697

GLOMTHERA is a trademark filed by Purespring Therapeutics Limited on January 9, 2026. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

Purespring Therapeutics Limited (7 trademarks)

8 Bloomsbury Street

Entity Type: 99

Trademark Details

Filing Date

January 9, 2026

Registration Date

Not Registered

Goods & Services

Pharmaceutical, medical and veterinary preparations and substances for the prevention, diagnosis and treatment of kidney diseases; reagents for use in medical genetic testing; biological, chemical and biochemical reagents for medical use; gene therapy products for medical and veterinary use; medical and veterinary preparations containing therapeutic DNA and RNA; biological, chemical, and biochemical reagents for medical purposes; pharmaceutical preparations, biological preparations, and gene therapy products for medical or pharmaceutical purposes, including, gene therapies, viral vectors, and nucleic-acid delivery products for use in the treatment of kidney diseases and disorders; pharmaceutical preparations for use in gene therapy; viral vectors for use in the delivery of gene therapy; adeno-associated virus (AAV) gene therapy; drug delivery agents consisting of capsids that facilitate delivery of pharmaceuticals and biopharmaceuticals; vaccines.

Pharmaceutical, medical and scientific research; providing scientific research information; research in the field of gene therapy; services for assessing the efficiency of pharmaceutical and medical preparations and substances; clinical trials; pharmaceutical and biopharmaceutical drug development services; research, and development of pharmaceutical preparations for gene therapy; biotechnology research services; research and development of platform technologies for genetic delivery of therapies and pharmaceuticals; research and development regarding the use of screening platforms to discover, research and develop novel capsids for genetic delivery of gene therapies and pharmaceuticals; research and development regarding the identification and targeting of specific cells and tissues for gene therapy delivery; providing medical and scientific research information on the prevention, diagnosis, and treatment of kidney diseases; providing a website featuring medical information and medical research; platform as a service (PaaS) featuring computer software platforms in the field of drug discovery and drug development.

Pharmaceutical and medical services; medical diagnostic and screening services; health care services; advisory services in the fields of medicine and pharmacology; consultancy and information services relating to pharmaceutical and medical preparations and substances; medical diagnosis and treatment of kidney diseases; medical testing, analysis, reporting, assessment and monitoring services relating to the treatment and management of kidney diseases; pharmaceutical and medical information.

Filing History

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
May 14, 2026 RFCR
NON-FINAL ACTION WRITTEN
May 13, 2026 CNRT
ASSIGNED TO EXAMINER
May 7, 2026 DOCK
APPLICATION FILING RECEIPT MAILED
Mar 15, 2026 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 15, 2026 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Mar 12, 2026 REPR